Who makes Theraprofen?

Theraprofen is developed by Targeted Medical Pharma.

What development phase is Theraprofen in?

Theraprofen is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Theraprofen

Targeted Medical Pharma · FDA-approved active Small molecule Quality 0/100

Theraprofen, marketed by Targeted Medical Pharma, is a drug with an unspecified mechanism and primary indication, currently generating unknown revenue. The key composition patent for Theraprofen is set to expire in 2028, which may provide a period of market exclusivity and competitive advantage. The primary risk is the lack of detailed clinical trial results and competitor information, which could impact market positioning and future revenue streams.

At a glance

Generic name	Theraprofen
Sponsor	Targeted Medical Pharma
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Double Blind Placebo Study to Determine the Effectiveness of Theramine on the Management of Chronic Back Pain (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Theraprofen CI brief — competitive landscape report
Theraprofen updates RSS · CI watch RSS
Targeted Medical Pharma portfolio CI